Catalog No.: PC-72400Not For Human Use, Lab Use Only.
JNJ-61803534 (JNJ 61803534) is a novel, selective and potent RORγt inverse agonist, inhibits RORγt-driven transcription with IC50 of 9.6 nM in 1-hybrid reporter assays.
JNJ-61803534 (JNJ 61803534) is a novel, selective and potent RORγt inverse agonist, inhibits RORγt-driven transcription with IC50 of 9.6 nM in 1-hybrid reporter assays.
JNJ-61803534 demonstrated high selectivity for RORγt over RORα and RORβ (IC50>2 uM), as well as against 18 human nuclear receptors and a panel of 52 receptors, ion channels and transporters, 28 GPCRs.
JNJ-61803534 dose-dependently suppressed production of IL-17A, IL-17F and IL-22 with IC50 values of 19nM, 22 nM and 27 nM, respectively, in human CD4+ T cells under Th17 differentiation, does not impair human nTreg suppressive function.
JNJ-61803534 specifically blocked RORγt-dependent pathways in cellular assays and significantly reduced inflammation in preclinical models.
